Your browser doesn't support javascript.
loading
Slow-Coagulation Transscleral Cyclophotocoagulation Laser Treatment for Medically Uncontrolled Secondary Aphakic Adult Glaucoma.
Elhusseiny, Abdelrahman M; Khodeiry, Mohamed M; Liu, Xiangxiang; Sayed, Mohamed S; Lee, Richard K.
Afiliação
  • Elhusseiny AM; Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Khodeiry MM; Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.
  • Liu X; Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.
  • Sayed MS; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA.
  • Lee RK; Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.
J Glaucoma ; 32(8): 695-700, 2023 08 01.
Article em En | MEDLINE | ID: mdl-37172013
PRCIS: Slow-coagulation CW-TSCPC is an efficacious, relatively safe, and non-incisional laser treatment option as an initial surgical glaucoma management choice, in secondary aphakic adult glaucoma that is medically uncontrolled. PURPOSE: This study evaluates the outcomes of slow-coagulation continuous wave transscleral cyclophotocoagulation (CW-TSCPC) laser for treating secondary aphakic adult glaucoma after complicated cataract surgery as a primary surgical intervention. MATERIALS AND METHODS: A retrospective chart review of adult aphakic eyes with medically uncontrolled glaucoma underwent slow-coagulation CW-TSCPC as a primary surgical glaucoma intervention was performed. Surgical success was the primary outcome measure. Success was defined as postoperative intraocular pressure (IOP) between 6 and 21 mm Hg with ≥20% reduction compared with baseline and no need for further glaucoma surgeries or development of vision-threatening complications. The secondary outcomes included changes in IOP, glaucoma medication numbers, visual acuity, and postoperative complications during the first year after laser treatment after laser treatment. RESULTS: This study included 41 eyes of 41 patients. The mean age of study participants was 66.7±13.1 years, with a mean follow-up duration of 19±3.5 months. At one year, the success rate was 63.4%. A statistically significant reduction of the IOP was observed, with the mean IOP decreasing from 29.6±5.8 mm Hg with a mean of 3.9±1.0 medications at baseline to a mean of 19.0±6.4 mm Hg with a mean of 2.5±1.2 medications at 12 months ( P <0.001). Four eyes received CW-TSCPC retreatment, and 2 eyes required incisional glaucoma surgeries. Reported postoperative complications included: visual acuity decline ≥2 lines in 7 eyes, iritis in 6 eyes, hyphema in 5 eyes, cystoid macular edema in 2 eyes, and transient hypotony in 1 eye. CONCLUSION: Slow-coagulation CW-TSCPC is an efficacious, relatively safe, and non-incisional laser treatment option as an initial surgical glaucoma management choice, in secondary aphakic adult glaucoma that is medically uncontrolled.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glaucoma / Pressão Intraocular Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Revista: J Glaucoma Assunto da revista: OFTALMOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glaucoma / Pressão Intraocular Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Revista: J Glaucoma Assunto da revista: OFTALMOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos